Bivalirudin in the cardiac cath lab: streamlining the percutaneous coronary intervention experience.
The common reasons that physicians do not use bivalirudin include concerns about cost, ease and speed of administration and difficulties knowing when to pull sheaths in the recovery area. We suggest that the use of bivalirudin in percutaneous coronary intervention (PCI) can reduce overall cath lab costs, does not delay care in coronary intervention and can actually reduce overall recovery time compared to traditional heparin-based therapy.